NO20044192L - 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater - Google Patents

17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater

Info

Publication number: NO20044192L
Authority: NO; Norway
Prior art keywords: ostratrienes; 17alpha; 17beta; oxy; alkyl
Prior art date: 2001-11-27

Application number

NO20044192A

Other languages

English (en)

Inventor

Rolf Bohlmann

Orlin Petrov

Nikolaus Heinrich

Jorg Kroll

Jens Hoffmann

Rosemarie Lichtner

Rolf Jautelat

Andreas Reichel

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-27

Filing date

2004-10-04

Publication date

2004-10-04

2004-10-04 Application filed by Schering Ag filed Critical Schering Ag

2004-10-04 Publication of NO20044192L publication Critical patent/NO20044192L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20044192A 2001-11-27 2004-10-04 17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater NO20044192L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10159217A DE10159217A1 (de)	2001-11-27	2001-11-27	17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
PCT/EP2002/013484 WO2003045972A1 (de)	2001-11-27	2002-11-27	17α-ALKYL-17β-OXY-ESTRATRIENE UND ZWISCHENPRODUKTE ZU DEREN HERSTELLUNG, VERWENDUNG DER 17α-ALKYL-17β-OXY-ESTRATRIENE ZUR HERSTELLUNG VON ARZNEIMITTELN SOWIE PHARMAZEUTISCHE PRÄPARATE

Publications (1)

Publication Number	Publication Date
NO20044192L true NO20044192L (no)	2004-10-04

Family

ID=7707804

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20042694A NO326241B1 (no)	2001-11-27	2004-06-25	17 alfa-alkyl-17 beta-oksy-ostratriener og mellomprodukter for fremstilling av disse, anvendelse av 17 alfa-alkyl-17 beta-oksy-ostratrienene til fremstilling av legemidler samt farmasoytiske preparater
NO20044192A NO20044192L (no)	2001-11-27	2004-10-04	17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO20042694A NO326241B1 (no)	2001-11-27	2004-06-25	17 alfa-alkyl-17 beta-oksy-ostratriener og mellomprodukter for fremstilling av disse, anvendelse av 17 alfa-alkyl-17 beta-oksy-ostratrienene til fremstilling av legemidler samt farmasoytiske preparater

Country Status (25)

Country	Link
US (2)	US7018994B2 (no)
EP (2)	EP1448591B1 (no)
JP (3)	JP2005513039A (no)
KR (1)	KR100956912B1 (no)
CN (2)	CN1325507C (no)
AR (1)	AR037674A1 (no)
AT (1)	ATE396198T1 (no)
AU (1)	AU2002360949A1 (no)
BR (1)	BR0214469A (no)
CA (1)	CA2468412C (no)
CY (1)	CY1108279T1 (no)
DE (2)	DE10159217A1 (no)
DK (1)	DK1448591T3 (no)
ES (1)	ES2307819T3 (no)
IL (2)	IL162200A0 (no)
MX (1)	MXPA04005015A (no)
NO (2)	NO326241B1 (no)
PE (1)	PE20030727A1 (no)
PL (1)	PL207955B1 (no)
PT (1)	PT1448591E (no)
RU (2)	RU2339643C2 (no)
TW (1)	TWI256891B (no)
UY (1)	UY27552A1 (no)
WO (1)	WO2003045972A1 (no)
ZA (2)	ZA200405029B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10159217A1 (de)	2001-11-27	2003-06-05	Schering Ag	17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US7731947B2 (en) *	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20040242551A1 (en) *	2003-05-28	2004-12-02	Schering Ag	Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
KR20070061526A (ko)	2004-07-27	2007-06-13	시코르, 인크.	7α-알킬화 19-노르스테로이드의 제조 방법
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
AU2007284759B2 (en)	2006-08-09	2010-10-28	Intarcia Therapeutics, Inc.	Osmotic delivery systems and piston assemblies
JP4724073B2 (ja)	2006-08-17	2011-07-13	富士通株式会社	レジストパターンの形成方法、半導体装置及びその製造方法
DE102007049630A1 (de)	2007-10-11	2009-10-29	Bayer Schering Pharma Aktiengesellschaft	Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007023614A1 (de)	2007-05-21	2008-11-27	Bayer Schering Pharma Aktiengesellschaft	Nichtsteroidale Progesteronrezeptor-Modulatoren
RU2440097C2 (ru)	2007-04-23	2012-01-20	Интарсия Терапьютикс, Инк.	Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
DE102007032800A1 (de)	2007-07-10	2009-01-15	Bayer Schering Pharma Aktiengesellschaft	Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2033948A1 (en) *	2007-08-30	2009-03-11	Bayer Schering Pharma Aktiengesellschaft	Process for preparing Estrogen-antagonistic 11beta-Fluoro-17alpha-alkylestra-1,3,5 (10)-triene-3, 17-diols having a 7alpha-(xi-Alkylamino-omega-perfluoroalkyl)alkyl side chain and alpha-Alkyl(amino)-omega-perfluoro(alkyl)alkanes and processes for their preparation
DE102007058747A1 (de)	2007-12-05	2009-06-10	Bayer Schering Pharma Aktiengesellschaft	Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070942A1 (de)	2007-12-13	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Verfahren zur Aromatisierung von 19-Nor-androst-4-en-3-onen zu Estra-1,3,5(10)-trienen
EP2070941A1 (en)	2007-12-14	2009-06-17	Bayer Schering Pharma Aktiengesellschaft	Stereoselective synthesis of selective estrogen receptor down-regulators
EP2070909A1 (de)	2007-12-15	2009-06-17	Bayer Schering Pharma AG	Nichtsteroidale Progesteronrezeptor-Modulatoren
US8343140B2 (en)	2008-02-13	2013-01-01	Intarcia Therapeutics, Inc.	Devices, formulations, and methods for delivery of multiple beneficial agents
DE102008057230A1 (de)	2008-11-11	2010-05-12	Bayer Schering Pharma Aktiengesellschaft	Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
EP2258375A1 (de) *	2009-06-04	2010-12-08	Bayer Schering Pharma Aktiengesellschaft	17B-alkyl-17alpha-oxy-estratriene
DE102009034366A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de)	2009-07-20	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de)	2009-07-21	2011-01-27	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de)	2009-07-21	2011-02-10	Bayer Schering Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
WO2011037623A1 (en)	2009-09-28	2011-03-31	Intarcia Therapeutics, Inc.	Rapid establishment and/or termination of substantial steady-state drug delivery
DE102010007722A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
DE102010007719A1 (de)	2010-02-10	2011-08-11	Bayer Schering Pharma Aktiengesellschaft, 13353	Progesteronrezeptorantagonisten
AU2011267798B2 (en)	2010-06-16	2015-04-02	Endorecherche, Inc.	Methods of treating or preventing estrogen-related diseases
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
DE102011004899A1 (de)	2011-03-01	2012-09-06	Bayer Pharma Aktiengesellschaft	17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
MA38465A1 (fr)	2013-04-11	2017-02-28	Bayer Pharma AG	Forme posologique de l'antagoniste du récepteur de la progestérone
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es)	2015-06-03	2024-05-08	I2O Therapeutics Inc	Sistemas de colocación de implantes
CA3024479A1 (en)	2016-05-16	2017-11-23	Intarcia Therapeutics, Inc.	Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
JP7286542B2 (ja)	2017-01-03	2023-06-05	インターシアセラピューティクス，インコーポレイティド	Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US11624095B2 (en)	2017-09-27	2023-04-11	Case Western Reserve University	Method of quantifying HIV reservoirs by induced transcription based sequencing
RU2750488C1 (ru) *	2020-06-03	2021-06-28	Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН)	1,2,4-Оксадиазольные производные дезоксихолевой кислоты, обладающие простатопротекторным действием, гипохолестеринемической и противовоспалительной активностями
CN116535454A (zh) *	2023-04-28	2023-08-04	香港中文大学（深圳）	氟维司群类化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA931944A (en)	1970-04-24	1973-08-14	Anner Georg	Oestrogenically highly active steroids and process for their manufacture
GB8327256D0 (en) *	1983-10-12	1983-11-16	Ici Plc	Steroid derivatives
US4666885A (en)	1985-02-08	1987-05-19	Fernand Labrie	Combination therapy for treatment of female breast cancer
EP0310542B1 (de)	1987-10-01	1994-06-08	Schering Aktiengesellschaft	Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de)	1987-10-01	1989-04-13	Schering Ag	Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en)	1988-06-06	1988-07-13	Ici Plc	Therapeutic product
DE19510862A1 (de)	1995-03-16	1996-09-19	Schering Ag	Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
DE19622457A1 (de) *	1996-05-24	1997-11-27	Schering Ag	7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en)	1996-08-20	1999-02-02	Schering Ag	7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (de) *	1996-08-20	1998-02-26	Schering Ag	7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE69833182T2 (de)	1997-01-30	2006-08-24	Dsm Ip Assets B.V.	Strahlungshärtbare zusammensetzung
DE19706061A1 (de)	1997-02-07	1998-08-13	Schering Ag	Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) *	1997-12-23	2001-05-02	Schering Ag	11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE19807791A1 (de)	1998-02-19	1999-08-26	Schering Ag	Kombinationspräparat aus Östrogen und Antiöstrogen
DE10019171A1 (de)	2000-04-07	2001-10-18	Schering Ag	Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
CN1512886A (zh)	2000-10-18	2004-07-14	��ֹɷݹ�˾	抗孕激素预防和治疗激素依赖性疾病的用途
DE10159217A1 (de)	2001-11-27	2003-06-05	Schering Ag	17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en)	2003-05-28	2004-12-02	Schering Ag	Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

2001
- 2001-11-27 DE DE10159217A patent/DE10159217A1/de not_active Withdrawn
2002
- 2002-11-26 PE PE2002001136A patent/PE20030727A1/es not_active Application Discontinuation
- 2002-11-27 ES ES02795080T patent/ES2307819T3/es not_active Expired - Lifetime
- 2002-11-27 PT PT02795080T patent/PT1448591E/pt unknown
- 2002-11-27 WO PCT/EP2002/013484 patent/WO2003045972A1/de not_active Ceased
- 2002-11-27 DK DK02795080T patent/DK1448591T3/da active
- 2002-11-27 JP JP2003547421A patent/JP2005513039A/ja active Pending
- 2002-11-27 TW TW091134468A patent/TWI256891B/zh not_active IP Right Cessation
- 2002-11-27 PL PL369171A patent/PL207955B1/pl not_active IP Right Cessation
- 2002-11-27 CN CNB2004100861882A patent/CN1325507C/zh not_active Expired - Fee Related
- 2002-11-27 RU RU2006120215/04A patent/RU2339643C2/ru not_active IP Right Cessation
- 2002-11-27 AU AU2002360949A patent/AU2002360949A1/en not_active Abandoned
- 2002-11-27 RU RU2004119437/04A patent/RU2285009C2/ru not_active IP Right Cessation
- 2002-11-27 IL IL16220002A patent/IL162200A0/xx unknown
- 2002-11-27 CA CA002468412A patent/CA2468412C/en not_active Expired - Fee Related
- 2002-11-27 DE DE50212302T patent/DE50212302D1/de not_active Expired - Lifetime
- 2002-11-27 AR ARP020104555A patent/AR037674A1/es active IP Right Grant
- 2002-11-27 UY UY27552A patent/UY27552A1/es not_active Application Discontinuation
- 2002-11-27 EP EP02795080A patent/EP1448591B1/de not_active Expired - Lifetime
- 2002-11-27 AT AT02795080T patent/ATE396198T1/de active
- 2002-11-27 KR KR1020047008007A patent/KR100956912B1/ko not_active Expired - Fee Related
- 2002-11-27 BR BR0214469-7A patent/BR0214469A/pt not_active IP Right Cessation
- 2002-11-27 MX MXPA04005015A patent/MXPA04005015A/es active IP Right Grant
- 2002-11-27 EP EP08075102A patent/EP1916254A3/de not_active Withdrawn
- 2002-11-27 CN CNB028275837A patent/CN100558741C/zh not_active Expired - Fee Related
- 2002-11-27 US US10/305,418 patent/US7018994B2/en not_active Expired - Fee Related
2004
- 2004-05-27 IL IL162200A patent/IL162200A/en not_active IP Right Cessation
- 2004-06-24 ZA ZA200405029A patent/ZA200405029B/xx unknown
- 2004-06-25 NO NO20042694A patent/NO326241B1/no not_active IP Right Cessation
- 2004-09-29 ZA ZA200407868A patent/ZA200407868B/xx unknown
- 2004-10-04 NO NO20044192A patent/NO20044192L/no not_active Application Discontinuation
2005
- 2005-01-20 JP JP2005013016A patent/JP4335820B2/ja not_active Expired - Fee Related
- 2005-07-26 US US11/188,992 patent/US7538100B2/en not_active Expired - Fee Related
2006
- 2006-08-17 JP JP2006222528A patent/JP2006306896A/ja active Pending
2008
- 2008-08-21 CY CY20081100893T patent/CY1108279T1/el unknown

Also Published As

Publication number	Publication date
JP4335820B2 (ja)	2009-09-30
EP1916254A3 (de)	2012-11-14
PE20030727A1 (es)	2003-09-18
UY27552A1 (es)	2003-06-30
PT1448591E (pt)	2008-09-19
PL369171A1 (en)	2005-04-18
ZA200407868B (en)	2005-04-26
JP2005120110A (ja)	2005-05-12
CN1325507C (zh)	2007-07-11
MXPA04005015A (es)	2005-04-08
EP1448591A1 (de)	2004-08-25
RU2006120215A (ru)	2008-01-10
JP2005513039A (ja)	2005-05-12
AR037674A1 (es)	2004-12-01
CA2468412C (en)	2010-01-12
BR0214469A (pt)	2004-10-13
PL207955B1 (pl)	2011-02-28
ATE396198T1 (de)	2008-06-15
US7018994B2 (en)	2006-03-28
JP2006306896A (ja)	2006-11-09
TW200305426A (en)	2003-11-01
US20060009436A1 (en)	2006-01-12
IL162200A0 (en)	2005-11-20
HK1077832A1 (en)	2006-02-24
RU2339643C2 (ru)	2008-11-27
KR20040063158A (ko)	2004-07-12
ZA200405029B (en)	2009-07-29
CA2468412A1 (en)	2003-06-05
TWI256891B (en)	2006-06-21
DE50212302D1 (de)	2008-07-03
HK1079215A1 (en)	2006-03-31
NO20042694L (no)	2004-07-22
AU2002360949A1 (en)	2003-06-10
NO326241B1 (no)	2008-10-27
US20030191099A1 (en)	2003-10-09
CN1617879A (zh)	2005-05-18
EP1916254A2 (de)	2008-04-30
CY1108279T1 (el)	2014-02-12
DE10159217A1 (de)	2003-06-05
CN1637015A (zh)	2005-07-13
KR100956912B1 (ko)	2010-05-11
US7538100B2 (en)	2009-05-26
RU2285009C2 (ru)	2006-10-10
RU2004119437A (ru)	2005-07-10
IL162200A (en)	2010-06-30
DK1448591T3 (da)	2008-09-29
EP1448591B1 (de)	2008-05-21
WO2003045972A1 (de)	2003-06-05
CN100558741C (zh)	2009-11-11
ES2307819T3 (es)	2008-12-01

Publication	Publication Date	Title
NO20044192L (no)	2004-10-04	17alfa-alkyl-17beta-oksy-ostratriener og farmasoytiske preparater
NO20033556D0 (no)	2003-08-11	Farmasöytiske preparater
NO20071303L (no)	2001-07-27	Farmasoytiske preparater
DK1417175T3 (da)	2013-10-28	Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
KR20050009999A (ko)	2005-01-26	약제학적 제제
NO20021401D0 (no)	2002-03-20	Konazolinforbindelser og farmasöytiske preparater inneholdende slike forbindelser
DK1400518T3 (da)	2007-03-26	Heterocycliske forbindelser og lægemidler
DK1370128T3 (da)	2014-05-26	Kombineret ballepresse og ballevikler
DK1390389T3 (da)	2009-04-20	Cripto-blokerende antistoffer og anvendelser deraf
IS3007B (is)	2018-12-15	Ónæmisbælandi efnasambönd og efnablöndur
IS7948A (is)	2005-07-20	Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
NO20020304L (no)	2002-03-21	Konserverte farmasoytiske preparater
NO20041975L (no)	2005-07-16	Bicyklisk oksopyridin og oksopyrimidinderivater
DK1746375T3 (da)	2013-02-11	Oxygendrevet forbrændingssystem og anvendelser deraf
EE200300416A (et)	2003-12-15	Ravimvorm
NO20025357L (no)	2002-11-08	Antranylamider og deres anvendelse som legemidler
NO20035315D0 (no)	2003-11-28	Farmasöytiske kombinasjoner
IS2841B (is)	2013-08-15	Samstæða hluta og lyfjasamsetningar
DK1417189T3 (da)	2006-05-08	Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO20033506D0 (no)	2003-08-07	Parasittdrepende preparater og fremgangsmåter for anvendelse
IS7798A (is)	2005-04-11	Efnasambönd, lyfjablöndur og aðferðir
DK1407780T3 (da)	2013-05-13	Farmaceutisk stabile hæmostatiske præparater
NO20042693L (no)	2004-08-25	Kateterpreparat og anvendelser derav
NO20030156L (no)	2003-03-13	Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
DK1849468T3 (da)	2013-02-04	Farmaceutisk sammensætning omfattende roflumilast og levocetirizin

Legal Events

Date	Code	Title	Description
2010-08-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application